GLP-1 receptor agonists: Materials
Materials it needs
The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is
Made of- Pep Peptides and oligonucleotides criticality medium The active ingredient is a peptide, a short chain of amino acids, modified to resist breakdown [1].
- Lys Amino acids (lysine, methionine) criticality low Peptides are built from amino acids, either by chemical synthesis or in engineered cells.
- Exc Pharmaceutical excipients criticality low Salts, buffers and preservatives keep the peptide stable in the injection pen.
- Qz Silica sand criticality low The medicine is held in glass cartridges or vials, and glass is made mainly from silica sand.
as of 2026-11-11. No source gives material amounts per dose; criticality is the writer's judgement. Peptides rank medium because supply is tight: WHO says that even with rapid expansion in production, the medicines are projected to reach fewer than 10% of those who could benefit by 2030 [3].
Critical materials
The materials whose supply could hold it back
- No scarce raw material holds these medicines back: amino acids and excipients are made in large amounts for other uses.
- Supply falls far short of need: even with rapid expansion in production, WHO projects the medicines will reach fewer than 10% of those who could benefit by 2030, and it calls for action on manufacturing and affordability [3].
- Supply is concentrated in a few companies; Novo Nordisk says it holds 45.8% of the GLP-1 diabetes market by value [5].
as of 2026-11-11
Sources
- GLP-1-based therapy for obesity Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity World Health Organization, 2025
- Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026, Form 6-K) Novo Nordisk A/S, filed with the US Securities and Exchange Commission, 2026